Douglas Lane

Aaron Wukmir

Alex Fuhrman

- LifeVantage achieved **$229 million in revenue** and **$22 million in EBITDA** for fiscal year 2025, marking **over 14% revenue growth** from FY24, largely due to the MindBody GLP-1 System.  **[849146_2162511_1]** **[849146_2162511_4]**  The company projects **moderate growth** in its core business for FY26.  **[849146_2162511_4]** 
- The company announced the acquisition of **LoveBiome**, a direct selling company specializing in microbiome and gut health, on **September 3rd**, with closing anticipated on **October 1st** and full integration by **November 1st**.  **[849146_2162511_1]** 
- LifeVantage maintains a balanced capital allocation strategy, including a **quarterly dividend** (which has been increased annually for the past three years and included a special dividend in September 2023) and an active **share repurchase program** with **$17 million remaining** under its current authorization.  **[849146_2162511_4]** **[849146_2162511_5]** 
- The MindBody GLP-1 System, a key product, demonstrated an average **11 pounds weight loss** and a **9% decrease in overall body fat** over a 12-week study, notably with **no muscle loss**.  **[849146_2162511_2]**

Lifevantage (LFVN)